.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Chubb
Covington
QuintilesIMS
Fish and Richardson
Novartis
Farmers Insurance
Mallinckrodt
Deloitte

Generated: June 24, 2017

DrugPatentWatch Database Preview

TRICOR Drug Profile

« Back to Dashboard

What is the patent landscape for Tricor, and when can generic versions of Tricor launch?

Tricor is a drug marketed by Abbott and Abbvie and is included in three NDAs. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-six patent family members in forty-two countries.

The generic ingredient in TRICOR is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

Summary for Tradename: TRICOR

Patents:9
Applicants:2
NDAs:3
Suppliers / Packagers: see list14
Bulk Api Vendors: see list80
Clinical Trials: see list12
Patent Applications: see list5,581
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TRICOR at DailyMed

Pharmacology for Tradename: TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
TRICOR (MICRONIZED)
fenofibrate
CAPSULE;ORAL019304-003Jun 30, 1999DISCNYesNo► Subscribe► Subscribe
Abbvie
TRICOR (MICRONIZED)
fenofibrate
CAPSULE;ORAL019304-004Jun 30, 1999DISCNYesNo► Subscribe► Subscribe
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 2001DISCNYesNo6,074,670► Subscribe ► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-001Nov 5, 2004ABRXYesNo7,320,802► Subscribe ► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-002Nov 5, 2004ABRXYesYes7,041,319► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-003Sep 4, 20014,895,726► Subscribe
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 20014,895,726► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-001Nov 5, 20045,145,684► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-002Nov 5, 20045,145,684► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TRICOR

Drugname Dosage Strength RLD Submissiondate
fenofibrateTablets48 mgTricor7/1/2008
fenofibrateTablets145 mgTricor10/19/2007

Non-Orange Book Patents for Tradename: TRICOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,124,057Propellant-based nanoparticulate dry powder aerosols and method of making► Subscribe
7,998,507Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors► Subscribe
8,236,352Glipizide compositions► Subscribe
7,459,283Nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
6,316,029 Rapidly disintegrating solid oral dosage form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TRICOR

Country Document Number Estimated Expiration
Australia731964► Subscribe
Canada2372561► Subscribe
Japan2005206614► Subscribe
Japan4611641► Subscribe
European Patent Office1519715► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Medtronic
UBS
Chinese Patent Office
Teva
Healthtrust
US Department of Justice
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot